BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison - 2Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
- 3Instructions to Really Oversee Unsold SUVs in the Auto Business
- 4One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- 5Web designers for Independent ventures
- 6 US States for Fly Fishing
- Figure out How to Plan for Your Web-based Degree monetarily
- 4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Instructions to Explore the Universe of Vehicle Leases
- Extreme Manual for Purchasing Your Next Truck
- A definitive Bike Standoff: Decision in favor of Your Number one Ride
- The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- 7 Moves toward a Sound and Dynamic Way of life
